Compare Illumina, Inc. (ILMN) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Omnicom Group Inc. — how do they compare? Illumina, Inc. trades at $265 (market cap $39.95B), while Omnicom Group Inc. trades at $76.35 (market cap $20.97B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 4.19% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Omnicom Group Inc. for 63 Days on average.
| ILMN | OMC | |
|---|---|---|
Market Cap | $39.95B | $20.97B |
Volume | 3,169,503 | 2,092,899 |
Sector | Health | Media |
52-Week High | $293.69 | $88.94 |
52-Week Low | $91.00 | $67.27 |
Typical Hold Time | 83 Days | 63 Days |
Enterprise Value | $41.31B | $29.05B |
Dividend Yield | — | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $17.27B in 2025 but posted a net loss of -$54.50M due to elevated expenses. Recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings. Valuation metrics show a high P/E of 202.35 but attractive P/S of 0.84, while analyst consensus is mixed with a $104.67 price target.
OMC presents a value opportunity with its low P/S ratio and 4.2% dividend yield, offset by profitability concerns and high debt. The stock's 39% discount to consensus target suggests upside if margin improvements materialize from recent acquisitions. Key risks include advertising market volatility and integration challenges from the Interpublic deal. Institutional activity shows mixed positioning with recent trimming by major banks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
